venture capital | pharmaphorum

Saturday 28 February 2026

venture capital

Market Access

Panel at BIO-Europe

From roasts to billions: Navigating the biopharma investment...

At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.

News

Pile of 50 euro notes

Medicxi raises €500m for latest biotech fund

Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.

Market Access

molecule visual

Biotech ≠ tech: Why venture capital needs a new playbook for...

Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1

R&D

Petri dishes in a lab

Why I'm focused on the trillion-dollar AMR crisis everyone's...

AMR demands sustained commitment beyond conventional market incentives.

News

#InvestinBiotech yearly honeycomb on green background

UK biotech investment "holding firm", says BIA

The UK life sciences raised £1.23bn in venture capital investment in the first half of 2025, although there was a fallback in the second quarter.

News

Antoine Papiernik, chairman and managing partner at Sofinnova Partners

Sofinnova raises €1.2bn to back 'up to 60' companies

Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.